Clareo Health | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.
Presence of measurable disease per RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You may not be if
Laboratory and medical history parameters not within the Protocol-defined range.
Receipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.
Previous radiotherapy within 2 weeks of starting study therapy.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Has not recovered to ≤ Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.
Receipt of a live vaccine within 30 days of planned start of study therapy.
Active infection requiring systemic therapy.
Subjects who have any active or inactive autoimmune disease or syndrome.
